A Patient's Guide to NK/T-Cell Lymphoma Testing: What Each Test Is For, From Diagnosis to Transplant

Expert InsightsPublished：2026-07-09

Summary: The diagnosis and treatment of NK/T-cell lymphoma can involve a long list of tests, which can be confusing for patients and families. This guide explains the main tests used across four stages - initial diagnosis, treatment monitoring, complication screening, and pre-transplant evaluation - including tissue biopsy, immunohistochemistry, EBER in situ hybridization, FISH, next-generation sequencing (NGS), PD-L1 testing, comprehensive bone marrow evaluation, circulating tumor DNA (ctDNA) liquid biopsy, a seven-parameter functional flow cytometry panel for hemophagocytic lymphohistiocytosis (HLH), high-resolution HLA typing, and KIR genotyping. It explains what each test is designed to assess, how similar-looking tests differ, and why the results may matter for treatment decisions.

If you are being evaluated for, or have been diagnosed with, NK/T-cell lymphoma, a long list of test orders can feel overwhelming. Many patients and families have the same questions:

Do I really need this test?

These two tests look similar - are they testing the same thing?

Which results are especially important when doctors are watching for serious complications?

...

This guide walks through the major tests used during initial diagnosis, treatment monitoring, complication screening, and preparation for transplantation, with a focus on what each test does and why it may be clinically useful.

Accurate Diagnosis | Understanding the Disease Before Treatment Begins

Diagnosis is the foundation of treatment. The main goals are to confirm the lymphoma subtype, assess how aggressive it may be, and determine whether the disease has spread beyond the original site.

1. Tissue Biopsy | The Most Important Source of Diagnostic Evidence

A sample of the lesion is collected and examined under a microscope. NK/T-cell lymphoma often contains large areas of tissue necrosis, so an inadequate sample can lead to a missed diagnosis. Doctors may therefore recommend image-guided sampling from more than one area or an excisional biopsy to improve the chance of obtaining viable tumor tissue.

2. Expert Pathology Review | A Second Look at a Difficult Diagnosis

NK/T-cell lymphoma is rare and can be difficult to diagnose. Necrotic tissue may be confused with inflammation or with other types of lymphoma. For challenging cases, our hospital works with Prof. Zifen Gao, an expert in lymphoma pathology, for additional pathology review. A precise diagnosis is an important first step toward choosing the right treatment.

3. Immunohistochemistry (IHC) | Identifying the Tumor's Protein Profile

IHC uses antibodies to detect proteins expressed by tumor cells and is an important part of confirming the diagnosis:

Typical positive markers: CD2, cytoplasmic CD3epsilon, CD56, TIA-1, granzyme B, and perforin

Typical negative markers: CD20 and surface CD3

Ki-67, MYC, and CD30 may also be tested to provide additional information that can help guide treatment.

4. EBER In Situ Hybridization (EBER-ISH) | Detecting Epstein-Barr Virus in Tumor Cells

Approximately 90%-100% of NK/T-cell lymphomas are associated with Epstein-Barr virus (EBV). A positive EBER result strongly supports the diagnosis and is widely regarded as one of the key diagnostic standards.

5. FISH | Looking for Chromosomal Abnormalities

Fluorescence in situ hybridization (FISH) can identify certain chromosomal deletions or amplifications. Examples may include 6q21 deletion, PD-L1 amplification, STAT3 amplification, and TP53 deletion. Not every patient will have these abnormalities. When present, they may contribute to risk assessment, but their absence does not rule out the diagnosis.

6. T-Cell Receptor (TCR) Gene Rearrangement Testing | Assessing Clonality

This test can help distinguish a reactive or inflammatory process from a malignant clonal process. It may be added in diagnostically difficult cases and should always be interpreted together with the pathology findings.

7. Next-Generation Sequencing (NGS) | Mapping the Tumor's Genetic Changes

NGS can screen multiple clinically relevant gene alterations at the same time. These may include:

Tumor suppressor gene inactivation: TP53 and DDX3X (frequently mutated and associated with higher-risk disease)
Activation of oncogenic pathways: STAT3 and STAT5B
Epigenetic alterations: KMT2D, BCOR, and ARID1A

If an ECSIT V140A variant is detected, clinicians should be particularly alert to the possibility of secondary hemophagocytic lymphohistiocytosis (HLH).

8. PD-L1 (SP263) Testing | Assessing Potential Suitability for Immunotherapy

Around 30%-70% of patients may show high PD-L1 expression. Doctors interpret this result together with other factors, such as disease stage and EBV DNA level, before deciding whether immunotherapy may be appropriate.

9. Comprehensive Bone Marrow Evaluation | Checking for Systemic Involvement

Bone marrow testing may be recommended for patients with anemia, thrombocytopenia, multiple suspicious lesions, or other high-risk features. The evaluation may include bone marrow aspiration, bone marrow biopsy, and flow cytometric immunophenotyping.

Treatment Monitoring | A Dynamic View of Disease Through the Blood

ctDNA Liquid Biopsy | Tracking Changes During Treatment

A blood test can measure circulating tumor DNA (ctDNA), fragments of tumor-derived DNA released into the bloodstream. Falling levels may suggest that treatment is working, while rising levels may raise concern for disease recurrence. However, ctDNA does not replace a tissue biopsy. If your doctor recommends another biopsy, it remains important to follow that advice.

Complication Screening | Watching Closely for Hemophagocytic Lymphohistiocytosis (HLH)

HLH secondary to NK/T-cell lymphoma is a medical emergency. If persistent high fever, pancytopenia, or enlargement of the liver or spleen occurs, a complete HLH evaluation should be arranged promptly.

Seven-Parameter Functional Flow Cytometry Panel for HLH | Assessing Immune Cell Function

This panel evaluates NK-cell activity together with CD107a, perforin, granzyme B, MUNC13-4, SAP, and XIAP. It helps assess whether immune-cell killing function is impaired and can support the distinction between primary (genetic) HLH and secondary, tumor-associated HLH.

10-Cytokine Panel | Measuring the Intensity of Systemic Inflammation

This panel helps quantify inflammatory activity and can support both HLH diagnosis and treatment monitoring. Important markers may include CXCL9, IFN-gamma, and sCD163. CXCL9 is considered a sensitive marker in NK/T-cell lymphoma-associated HLH.

EBV-Infected Cell Subset Analysis | Identifying Which Immune Cells Carry the Virus

This test determines which immune-cell population is predominantly infected by EBV - T cells, B cells, or NK cells. If T/NK cells are mainly involved, the HLH may be more closely related to NK/T-cell lymphoma; if B cells are predominantly involved, doctors may need to consider other possibilities.

NGS Genetic Testing | Distinguishing Primary from Secondary HLH

Testing for genes associated with primary HLH, such as PRF1 and UNC13D, can help determine whether HLH is inherited or secondary to the lymphoma. This distinction can be important when planning treatment and selecting a stem cell donor.

Pre-Transplant Evaluation | Preparing as Safely as Possible for Stem Cell Transplantation

For some patients with high-risk, relapsed, or refractory disease, allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be an important potentially curative treatment. Pre-transplant testing focuses on identifying the most suitable donor, reducing the risk of graft rejection, and avoiding the use of a donor who may carry the same inherited disease-causing variant.

1. High-Resolution HLA Typing | Assessing Donor-Recipient Immune Compatibility

HLA molecules help the immune system distinguish self from non-self. In general, closer HLA matching is associated with a lower risk of immune incompatibility. Testing commonly includes six key loci: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1.

2. KIR Genotyping | Evaluating Donor NK-Cell Characteristics

KIR genotyping examines regulatory genes on donor NK cells and may provide additional information about the donor's potential antitumor immune activity, helping clinicians optimize donor selection.

3. Donor-Specific Antibody (DSA) Testing | Identifying Risk of Graft Rejection

This test checks whether the patient has antibodies directed against the donor's HLA. A positive result can substantially increase the risk of graft rejection or engraftment failure, and may require treatment before transplant or selection of a different donor. Because DSA levels can change over time, the test should be repeated within four weeks before transplantation.

4. Whole-Exome Sequencing for Inherited Predisposition | Screening Patient and Donor for Germline Risk

Testing both the patient and potential donor has two main goals:

Screen for disease-causing inherited variants associated with conditions such as HLH, helping avoid selection of a donor who carries the same pathogenic variant and could potentially recreate the same inherited immune defect after transplant.
Assess potential long-term prognostic risks.

Precision Treatment Starts with an Accurate Diagnosis

Understand why each test has been ordered
Know what each result may contribute to your care
Stay in close communication with your treating team and complete recommended testing

With clear information, appropriate testing, and regular follow-up, patients and families can move through each stage of treatment with greater confidence.

This article is for general educational purposes only. The tests and treatment plan that are appropriate for you should be determined by your treating physician.